H.C. Wainwright slashes price target on vTv Therapeutics Inc. [VTVT] – find out why.

vTv Therapeutics Inc. [NASDAQ: VTVT] surged by $0.01 during the normal trading session on Friday and reaching a high of $2.259 during the day while it closed the day at $2.22. The company report on June 29, 2021 that vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737.

>> 7 Top Picks for the Post-Pandemic Economy <<

vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, announced that it will be presenting data from the clinical development of HPP737 as a treatment for psoriasis in a poster presentation at the 6th World Psoriasis & Psoriatic Arthritis Conference held virtually June 30 – July 3, 2021 in Stockholm, Sweden.

Poster Details:.

vTv Therapeutics Inc. stock has also loss -3.06% of its value over the past 7 days. However, VTVT stock has declined by -21.55% in the 3 months of the year. Over the past six months meanwhile, it has gained 19.35% and gained 19.35% year-on date.

The market cap for VTVT stock reached $184.10 million, with 56.47 million shares outstanding and 22.52 million shares in the current float. Compared to the average trading volume of 5.87M shares, VTVT reached a trading volume of 873975 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about vTv Therapeutics Inc. [VTVT]:

H.C. Wainwright have made an estimate for vTv Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 30, 2019. While these analysts kept the previous recommendation, Stifel dropped their target price from $12 to $1. The new note on the price target was released on April 10, 2018, representing the official price target for vTv Therapeutics Inc. stock. Previously, the target price had yet another raise to $17, while ROTH Capital analysts kept a Buy rating on VTVT stock.

The Average True Range (ATR) for vTv Therapeutics Inc. is set at 0.15, with the Price to Sales ratio for VTVT stock in the period of the last 12 months amounting to 24.88.

VTVT stock trade performance evaluation

vTv Therapeutics Inc. [VTVT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.06. With this latest performance, VTVT shares dropped by -7.11% in over the last four-week period, additionally plugging by 19.35% over the last 6 months – not to mention a drop of -2.20% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VTVT stock in for the last two-week period is set at 37.06, with the RSI for the last a single of trading hit 31.70, and the three-weeks RSI is set at 40.67 for vTv Therapeutics Inc. [VTVT]. The present Moving Average for the last 50 days of trading for this stock 2.45, while it was recorded at 2.25 for the last single week of trading, and 2.28 for the last 200 days.

vTv Therapeutics Inc. [VTVT]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and vTv Therapeutics Inc. [VTVT] shares currently have an operating margin of -184.78. vTv Therapeutics Inc.’s Net Margin is presently recorded at -132.51.

Reflecting on the efficiency of the workforce at the company, vTv Therapeutics Inc. [VTVT] managed to generate an average of -$339,960 per employee. Receivables Turnover for the company is 78.70 with a Total Asset Turnover recorded at a value of 0.53.vTv Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 1.80.

vTv Therapeutics Inc. [VTVT]: Insider Ownership positions

There are presently around $11 million, or 8.00% of VTVT stock, in the hands of institutional investors. The top three institutional holders of VTVT stocks are: VANGUARD GROUP INC with ownership of 807,578, which is approximately 12.578% of the company’s market cap and around 0.10% of the total institutional ownership; NUVEEN ASSET MANAGEMENT, LLC, holding 744,848 shares of the stock with an approximate value of $1.65 million in VTVT stocks shares; and BLACKROCK INC., currently with $1.06 million in VTVT stock with ownership of nearly 8.168% of the company’s market capitalization.

>> 7 Top Picks for the Post-Pandemic Economy <<

Positions in vTv Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 35 institutional holders increased their position in vTv Therapeutics Inc. [NASDAQ:VTVT] by around 2,546,971 shares. Additionally, 17 investors decreased positions by around 235,943 shares, while 5 investors held positions by with 2,015,572 shares. The mentioned changes placed institutional holdings at 4,798,486 shares, according to the latest SEC report filing. VTVT stock had 13 new institutional investments in for a total of 1,122,047 shares, while 8 institutional investors sold positions of 198,205 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam